The company's MAR-T cell technology achieved an 84.6% disease control rate in pancreatic cancer when combined with frontline chemotherapy. Marker plans a company-sponsored trial with expanded antigen targets, higher cell doses and lymphodepletion, with anticipated clinical initiation in H1 2026, supported by non-dilutive government funding.
Cyborg Score Rationale
The company demonstrates strong clinical validation with promising efficacy data in pancreatic cancer and analyst support (Strong Buy rating with 500%+ upside potential). However, pre-commercial stage, losses continuing through 2026-2027, extremely low stock price ($1.31 as of June 25, 2026), and micro-cap status present substantial execution and capital risks.
Top Insights
(January 2026) Baylor College of Medicine published TACTOPS pancreatic cancer data showing 84.6% disease control rate with favorable safety profile
(February 2026) CEO presented at Oppenheimer Healthcare Life Sciences Conference on MAR-T platform progress
(May 2026) Shareholders approved governance changes; analysts maintained Buy rating with clinical milestones anticipated in Q2 2026
Company-sponsored trial anticipated to initiate in H1 2026 with expanded antigen targets and higher cell doses
Named Competitors
CAR-T Cell Therapy — Engineered cell immunotherapies for hematologic malignancies
Yescarta — CAR-T cell therapy for lymphomas
Tecartus — CAR-T cell therapy for B-cell malignancies
Recent Developments
(January 2026) Baylor study featured on Good Morning America and published in Nature Medicine showing 84.6% disease control rate in pancreatic cancer
(May 2026) Shareholders approved capital structure and governance changes; Buy rating reaffirmed with $8 price target
(Q1 2026) Reported EPS of -$0.16, beating estimates; stock at micro-cap valuation under $2
Open the full interactive Marker Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.